Summary Twenty patients with non-Hodgkin's lymphoma were treated with a combination of cyclophosphamide (750 mg m-2, day 1), epidoxorubicin (60 mg m-2, day 1), vincristine (1.4 mg m-2, day 1) and prednisone (100 mg m-2, days 1-5) every 14 days. Shortening of intervals was associated with the prophylactic employment of granulocyte colony-stimulating factor (G-CSF; specifically, filgrastim) administered at a dose of 300 gg subcutaneously from day 6 to day 11. The ratio between actually delivered dose intensity and planned dose intensity was 1.0 in 18 out the 20 patients. Toxicity was acceptable; response rate and survival are in the expected range. The present study demonstrated the feasibility of acceleration of chemotherapy cycles to obtain dose intensification in non-Hodgkin's lymphoma.
Non-Hodgkin's lymphomas represent a large family of neoplastic diseases with heterogeneous natural history; a series of different therapeutic approaches should be considered. Chemotherapy is the mainstay of treatment for many patients, mainly for the intermediate-to high-grade forms.
An association between dose of chemotherapeutic agents and anti-tumour effect has been established in several experimental models and suggested in a few clinical reports (Gurney et al, 1993a,b) ; the availability of haematopoietic growth factors (G-CSF, granulocyte colony-stimulating factor; and GM-CSF, granulocyte-macrophage colony-stimulating factor) has rendered safer the administration of conventional chemotherapy and feasible a series of experiments on chemotherapy dose intensification.
In the present study we investigated the intensification of chemotherapy in combination with G-CSF, by shortening intervals among cycles, in analogy with studies of chemotherapy acceleration carried out in breast (Ardizzoni et al, 1994) , ovarian (Pronzato et al, 1996) , bladder (Pronzato et al, 1997 ) and small-cell lung cancer (Ardizzon et al, 1993) .
PATIENTS AND METHODS Patients
To enter this study patients were required to fulfil the following criteria: histological diagnosis of non-Hodgkin's lymphoma; histological features of intermediate-or high-grade lymphoma according to the Working Formulation (excluding lymphoblastic lymphoma) groups D, E, F, G, H and J; absence of cardiovascular diseases on the basis of clinical examination and electrocardiogram (ECG); adequate marrow reserve (pretreatment values, Hb > 10 g dl-'; WBC > 3.5 x 109 1-1; platelets > 150 x 109 1-1); a serum creatinine level of < 1.0 mg dl-'; a serum bilirubin level of < 1.2 mg/dl; no concomitant acquired immunodeficiency syndrome; no concomitant neoplastic diseases. The patients had to be previously untreated by chemotherapy. The nature and the purpose of the study were discussed fully with all patients and informed consent was obtained from all those enrolled.
Treatment
Patients were treated with the following regimen (accelerated CEOP): cyclophosphamide 750 mg m-2 i.v. day 1; epidoxorubicin 60 mg m-2 i.v. day 1: vincristine 1.4 mg m-2 i.v. day 1; prednisone 100 mg/M-2 orally day 1-5; G-CSF (filgrastim) 300 ,ug subcutaneously days 6-11. All the patients received an antiemetic premedication by ondansetron. Cycles were repeated every 14 days provided that bone marrow recovery had occurred on the day of recycle (WBC > 3.0 x 109 1-1 and platelets > 100 x 109 1-'). In the case of incomplete marrow recovery, delays were planned for all the drugs until the above-mentioned values were reached. Response and toxicity were evaluated by the WHO criteria (Miller et al, 1981) .
Study design
We planned this study to evaluate the feasibility of dose intensification by acceleration, considering a therapeutic success (in terms of dose intensity) the achievement of at least 80% of the planned dose intensity (actually received-planned dose intensity ratio) in six cycles, on the basis of our previous experience in breast cancer 777 (Pronzato, 1989) . The dose intensity, expressed in milligrams per square metre of body surface area per week, was calculated for each drug by dividing the total amount of drug (planned or received) by the duration of chemotherapy (Hryniuk, 1984) . The ratio between the actually received dose intensity and the planned dose intensity was the same for each drug, as no differential reductions in dose or delays in time of administration were foreseen or applied. To determine the sample size minimizing the number of patients receiving a 'not feasible treatment', we applied the Simon's two-stage minimax design for phase II clinical trials (Simon, 1989 Nine patients with limited disease were treated with radiotherapy of the involved fields only after the last cycle of chemotherapy was administered. Two patients with disseminated disease experiencing a complete response were treated with consolidation chemotherapy. However, the present study regards only the analysis of the first six consecutive cycles of accelerated CEOP. At the end of the first stage of accrual we noted that 14 out of the 16 patients entered had completed the programme with a ratio of actually received-planned dose intensity of 1.0. Early acceptance of the treatment is not permitted at the end of the first stage, and a further four patients were entered, again achieving adequate dose intensity. Overall, 18 patients received six cycles without delay or dose reduction and two patients had a delay of 1 and 2 weeks. In Table 2 the drug dose intensities of different regimens are shown. As can be seen the dose intensity (planned and actually received) for cyclophosphamide and anthracycline was higher in the present trial than in classical regimens.
Maintenance of the planned dose intensity (100% of the dose at due times), low toxicity, good acceptance of the acceleration by the patients and our previous experience with accelerated chemotherapy prompted us to stop the trial even though the second stage of the accrual was not completed. We observed 15 objective responses (eight complete and seven partial). Median survival was 24 months (range 6-36+). Median survival of responders was 32 months (12+-36+)
Toxicity was moderate in this study; the main side-effects of chemotherapy and filgrastim are shown in Table 3 . Notably, all the treatment was administered in an outpatient setting and no patient needed to be admitted because of treatment toxicity. A mild decline in haemoglobin and platelets was observed during the treatment (Table 4) ; red cell transfusion was needed in three cases.
DISCUSSION
After classical combination chemotherapy -the so-called firstgeneration regimens -showed the ability to cure a fraction of patients with intermediate-to high-grade lymphoma, improvements were thought to be achieved by means of chemotherapy intensification dose (Fisher et al, 1983; Longo et al, 1991; Klimo and Connors, 1995) . Although preliminary studies invariably showed very high response rates for the so-called second-and third-generation regimens, a definitive demonstration of superiority over the firstgeneration combinations, in particular the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone), has not been reached (Fisher et al, 1993; Cooper et al, 1994) .
One of the theoretical reasons in favour of second-to thirdgeneration regimens is the dose intensification of chemotherapy; on the other hand, dose intensity of the two main drugs, i.e. cyclophosphamide and doxorubicin, decreased because of the concomitant use of other drugs (Fisher et al, 1993) . Dose intensity is defined as the amount of drug administered per unit of time (usually expressed as mg m-2 week-'); it was extensively studied in the 1980s by Hryniuk and his group (Hryniuk, 1984) . A retrospective analysis on the association between projected dose intensity of British Journal of Cancer (1998) 78(6), [777] [778] [779] [780] . Cancer Research Campaign 1998 Dose intensity in non-Hodgkin's lymphoma 779 22 different studies and their response rate showed that dose intensity may improve the remission rate in advanced-stage intermediate-grade lymphoma (Meyer et al, 1993) . A retrospective analysis showed a better survival for patients having received a relative dose intensity >70% of cyclophosphamide and doxorubicin (Lepage et al, 1993) . Also, a group at Stanford University (Kwak et al, 1990) found that actually received dose intensity is correlated with survival improvement: the received dose intensity of doxorubicin was the single most important predictor of survival.
In the LNH-84 protocol the induction chemotherapy was a high dose intensity sort of CHOP and the favourable results may be determined by the increased dose intensity of doxorubicin and cyclophosphamide (Coiffier, 1995) . Although these studies are retrospective in nature, they serve as a basis to the design of prospective trials specifically aimed at exploring the issue of dose intensity. The dose intensity of drugs included in cyclic combinations may be increased in two ways: increasing the doses of each cycle or shortening the intervals between cycles. Haematopoietic growth factors permit the shortening of intervals between cycles of chemotherapy, and G-CSF/GM-CSF have been demonstrated to be able to protect from consequences of leucopenia in the cases of conventional but aggressive regimens. Pettengell et al (1992) demonstrated that the protection from myelosuppression induced by VAPEC-B with the prophylactic use of filgrastim determined a more rapid recovery of neutrophils, resulting in a significantly lower incidence of dose reductions or cycle delays. Chemotherapy dose could be increased in two studies by means of G-CSF or GM-CSF (Shipp et al, 1995; Gordon et al, 1996) .
In a randomized study carried out in breast cancer patients the intervals between cycles of cyclophosphamide, epidoxorubicin and fluorouracil were reduced and the dose intensity increased by employment of GM-CSF (Ardizzoni et al, 1994) . In another study, in breast cancer, dose escalation and interval reduction were randomly compared, resulting in a higher dose intensity with the interval reduction (Lalisang et al, 1997) . In other pilot trials the acceleration was studied in ovarian (Kehoe et al, 1994; Pronzato et al, 1996) , bladder (Pronzato et al, 1997 ) and small-cell lung cancer (Ardizzoni et al, 1993) . In analogy with these trials of chemotherapy acceleration, we studied the shortenings of intervals between cycles of a combination of cyclophosphamide, epidoxorubicin, vincristine and prednisone. In this schedule we adopted epidoxorubicin instead of the parent compound doxorubicin, considering its more favourable toxic profile and assuming an anti-tumour equivalence of 1.2: 1.0, based on the fact that to achieve equimyelotoxicity epidoxorubicin should be administered at a dose 20% higher than that of doxorubicin (Mouridsen et al, 1990) . Therefore, our dose of epidoxorubicin may be considered analogous to that of doxorubicin in the classical CHOP, whereas the other two drugs were at the same dose as in the conventional CHOP. In this study, we obtained interesting results in terms of response rate and survival. Our scheme proved feasible and devoid of excessive toxicity, including use in older patients, who represent more than half of our series. Notably, all the treatments were carried out in an outpatient setting and admission was not needed in any case.
Acceleration may be an important way to achieve safe dose intensification. In advanced ovarian cancer the dose increase of each cycle with unchanged intervals did translate to an increase in sideeffects and limitation of dose intensification (Conte et al, 1996) . However, acceleration of the same drugs has been shown to be feasible (Pronzato et al, 1996) . In breast cancer, chemotherapy acceleration resulted in a more pronounced dose intensification with respect to increase in dosage per cycle (Lalisang et al, 1997) . Haematopoietic growth factors permitted safe acceleration of chemotherapy and, on the basis of the results obtained in the present and in other studies (Shipp et al, 1995; Gordon et al, 1996) , further dose intensifications may be achieved. Nevertheless, recent observations on the leucemogenic potential of alkylators/anthracycline dose intensification and growth factors should be taken into consideration (Brodsky et al, 1997; De Cillis et al, 1997) .
In conclusion, our scheme was feasible and active and, if one looks at dose intensification as a major issue, our accelerated regimen warrants further consideration in phase II-III trials.
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